How to buy Alterity Therapeutics stock (ATHE)

Alterity Therapeutics is a biotechnology business based in the US. Alterity Therapeutics shares (ATHE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.20 – a decrease of 8.33% over the previous week. Alterity Therapeutics employs 10 staff and has a trailing 12-month revenue of around $4 million.

Our top picks for where to buy Alterity Therapeutics stock

Buy Alterity Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Alterity Therapeutics stock price (NASDAQ: ATHE)

Use our graph to track the performance of ATHE stocks over time.

Alterity Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$2.20
52-week range	$1.00 - $3.19
50-day moving average more info button	$1.40
200-day moving average more info button	$1.66
Wall St. target price	$8.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-3.79

Is it a good time to buy Alterity Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alterity Therapeutics price performance over time

Historical closes compared with the close of $2.2 from 2024-12-20

1 week (2024-12-13)	-8.33%
1 month (2024-11-22)	105.61%
3 months (2024-09-20)	78.86%
6 months (2024-06-21)	24.29%

1 year (2023-12-22)	-17.60%
2 years (2022-12-22)	-29.03%
3 years (2021-12-22)	8.333
5 years (2019-12-20)	9.616

Alterity Therapeutics financials

Revenue TTM	$4 million
Gross profit TTM	$3.6 million
Return on assets TTM	-52.66%
Return on equity TTM	-104.47%
Profit margin	0%
Book value	$0.00
Market Capitalization more info button	$23.3 million

TTM: trailing 12 months

Alterity Therapeutics share dividends

We're not expecting Alterity Therapeutics to pay a dividend over the next 12 months.

Have Alterity Therapeutics's shares ever split?

Alterity Therapeutics's shares were split on a 1:10 basis on 8 January 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alterity Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Alterity Therapeutics shares which in turn could have impacted Alterity Therapeutics's share price.

Alterity Therapeutics share price volatility

Over the last 12 months, Alterity Therapeutics's shares have ranged in value from as little as $1.001 up to $3.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alterity Therapeutics's is 0.684. This would suggest that Alterity Therapeutics's shares are less volatile than average (for this exchange).

Alterity Therapeutics overview

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. .

Frequently asked questions

null
What percentage of Alterity Therapeutics is owned by institutions?
Currently 1.284% of Alterity Therapeutics shares are held by institutions. How many people work for Alterity Therapeutics?
Latest data suggests 10 work at Alterity Therapeutics. When does the fiscal year end for Alterity Therapeutics?
Alterity Therapeutics's fiscal year ends in June. Where is Alterity Therapeutics based?
Alterity Therapeutics's address is: 350 Collins Street, Melbourne, VIC, Australia, 3000 What is Alterity Therapeutics's ISIN number?
Alterity Therapeutics's international securities identification number is: US02155X1063 What is Alterity Therapeutics's CUSIP number?
Alterity Therapeutics's Committee on Uniform Securities Identification Procedures number is: 02155X106